KR20170047265A - 25-하이드록시비타민 d를 이용한 보조요법 - Google Patents

25-하이드록시비타민 d를 이용한 보조요법 Download PDF

Info

Publication number
KR20170047265A
KR20170047265A KR1020177006349A KR20177006349A KR20170047265A KR 20170047265 A KR20170047265 A KR 20170047265A KR 1020177006349 A KR1020177006349 A KR 1020177006349A KR 20177006349 A KR20177006349 A KR 20177006349A KR 20170047265 A KR20170047265 A KR 20170047265A
Authority
KR
South Korea
Prior art keywords
hydroxyvitamin
patient
effective amount
hypocalcemia
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177006349A
Other languages
English (en)
Korean (ko)
Inventor
피. 마틴 펫코비치
조엘 지. 멜닉
제이 에이. 화이트
사미르 피. 타바쉬
찰스 더블유. 비숍
수잔 에이취. 피얼스
스테픈 에이. 스트러그넬
Original Assignee
옵코 아일랜드 글로벌 홀딩스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53783233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20170047265(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 옵코 아일랜드 글로벌 홀딩스 리미티드 filed Critical 옵코 아일랜드 글로벌 홀딩스 리미티드
Publication of KR20170047265A publication Critical patent/KR20170047265A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177006349A 2014-08-07 2015-08-06 25-하이드록시비타민 d를 이용한 보조요법 Ceased KR20170047265A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462034604P 2014-08-07 2014-08-07
US62/034,604 2014-08-07
PCT/EP2015/068219 WO2016020508A2 (en) 2014-08-07 2015-08-06 Adjunctive therapy with 25-hydroxyvitamin d

Publications (1)

Publication Number Publication Date
KR20170047265A true KR20170047265A (ko) 2017-05-04

Family

ID=53783233

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177006349A Ceased KR20170047265A (ko) 2014-08-07 2015-08-06 25-하이드록시비타민 d를 이용한 보조요법
KR1020187011558A Active KR102677359B1 (ko) 2014-08-07 2016-02-10 25-하이드록시비타민 d를 이용한 보조요법 및 그 용품

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187011558A Active KR102677359B1 (ko) 2014-08-07 2016-02-10 25-하이드록시비타민 d를 이용한 보조요법 및 그 용품

Country Status (21)

Country Link
US (2) US20180085381A1 (enExample)
EP (1) EP3193925A2 (enExample)
JP (5) JP2017523220A (enExample)
KR (2) KR20170047265A (enExample)
CN (2) CN114681468A (enExample)
AU (2) AU2015298858A1 (enExample)
BR (1) BR112017002526A2 (enExample)
CA (1) CA2957240A1 (enExample)
CL (1) CL2017000317A1 (enExample)
CO (2) CO2018004206A2 (enExample)
CR (2) CR20170085A (enExample)
EA (1) EA201790332A1 (enExample)
EC (1) ECSP17014159A (enExample)
IL (1) IL250462A0 (enExample)
MX (1) MX2017001751A (enExample)
MY (1) MY203284A (enExample)
PE (1) PE20170392A1 (enExample)
PH (2) PH12017500228A1 (enExample)
SG (2) SG11201700858RA (enExample)
TW (2) TWI778934B (enExample)
WO (1) WO2016020508A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2640094C (en) 2006-02-03 2015-04-14 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
PL2679228T3 (pl) 2006-06-21 2018-07-31 Opko Ireland Global Holdings, Ltd. Terapia z użyciem środka do uzupełniania witaminy D i środka do zastępowania hormonami witaminy D
KR101495578B1 (ko) 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 ｄ 부족 및 결핍의 치료 방법
SI2481400T1 (sl) 2007-04-25 2014-11-28 Opko IP Holdings II, Inc. Nadzorovano oralno sproščanje sestavkov, ki vsebujejo spojino vitamina D in voskasti nosilec
EP3636280B1 (en) 2010-03-29 2025-05-14 EirGen Pharma Ltd. Methods and compositions for reducing parathyroid levels
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
SG10201913863TA (en) 2016-03-28 2020-03-30 Opko Ireland Global Holdings Limited Methods of vitamin d treatment
PT3246032T (pt) * 2016-05-20 2021-10-18 Christoph Karl Composições farmacêuticas com ácido zoledrónico, cálcio e vitamina d adequadas para tratamento e/ou profilaxia de doenças do metabolismo ósseo e de efeitos secundários relacionados com terapia, como hipocalcemias
US20190290756A1 (en) * 2016-05-20 2019-09-26 Christoph Karl Pharmaceutical compositions with anti-rankl antibodies, calcium and vitamin d
CN108519448B (zh) * 2018-04-04 2021-04-13 北京市心肺血管疾病研究所 25-羟基维生素d在制备大动脉炎患者疾病活动性评判试剂盒中的应用
MY210476A (en) 2018-08-31 2025-09-24 Opko Ireland Global Holdings Ltd Vitamin d pediatric dosage forms, methods of making and using
CA3176559A1 (en) * 2020-04-06 2021-10-14 Eirgen Pharma Ltd. 25-hydroxyvitamin d for the treatment of sars-cov-2 infection
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
AU2003220689A1 (en) * 2002-04-10 2003-10-27 Miller, Fred H Multi-phase, multi-compartment capsular system
AR040672A1 (es) * 2002-07-25 2005-04-13 Glaxo Group Ltd Forma de dosificacion farmaceutica multicomponenete, cuerpo apropiado para ser utilizado en la misma y procedimiento para prepararla
DE20321698U1 (de) * 2002-12-16 2008-12-24 Teva Pharmaceutical Industries Ltd. Medikament zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin-D-Derivats
US20100144679A1 (en) * 2007-03-21 2010-06-10 Duke University Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
FI3225243T3 (fi) * 2007-04-25 2025-10-13 Opko Renal Llc Menetelmä sekundaarisen hyperparatyreoosin turvalliseen ja tehokkaaseen hoitoon ja ehkäisyyn kroonisen munuaistaudin yhteydessä
CA2684778C (en) * 2007-04-25 2017-09-05 Cytochroma Inc. Methods and compounds for vitamin d therapy
SI2481400T1 (sl) * 2007-04-25 2014-11-28 Opko IP Holdings II, Inc. Nadzorovano oralno sproščanje sestavkov, ki vsebujejo spojino vitamina D in voskasti nosilec
KR101495578B1 (ko) * 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 ｄ 부족 및 결핍의 치료 방법
JP5509504B2 (ja) * 2008-02-13 2014-06-04 ディーエスエム アイピー アセッツ ビー．ブイ． 骨塩密度を改善し、骨粗鬆症を治療するための２５−ヒドロキシ−ビタミンｄ３とビタミンｄ３の併用
KR20120005228A (ko) * 2010-07-08 2012-01-16 주식회사 네비팜 골다공증 치료용 비스포스폰산 함유 장용 약학조성물 및 그의 제조방법
US20130085121A1 (en) * 2011-09-30 2013-04-04 Jianguo Wang Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
KR101847947B1 (ko) * 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형

Also Published As

Publication number Publication date
CN106604733A (zh) 2017-04-26
PH12017500228A1 (en) 2017-07-03
JP2025016586A (ja) 2025-02-04
WO2016020508A3 (en) 2016-03-31
CO2018004206A2 (es) 2018-09-20
IL250462A0 (en) 2017-03-30
US20200253988A1 (en) 2020-08-13
AU2020267276A1 (en) 2020-12-10
JP2023071723A (ja) 2023-05-23
AU2020267276B2 (en) 2022-12-08
SG10201911274TA (en) 2020-02-27
WO2016020508A2 (en) 2016-02-11
KR102677359B1 (ko) 2024-06-20
CL2017000317A1 (es) 2017-10-20
TW202241453A (zh) 2022-11-01
PH12020551759A1 (en) 2021-05-10
NZ728823A (en) 2024-01-26
CA2957240A1 (en) 2016-02-11
US20180085381A1 (en) 2018-03-29
CN114681468A (zh) 2022-07-01
CR20210577A (es) 2022-02-10
TWI778934B (zh) 2022-10-01
SG11201700858RA (en) 2017-03-30
TW201613607A (en) 2016-04-16
AU2015298858A1 (en) 2017-03-02
CR20170085A (es) 2017-04-25
CO2017002081A2 (es) 2017-07-19
JP2020203905A (ja) 2020-12-24
MX2017001751A (es) 2017-05-30
JP2023002606A (ja) 2023-01-10
BR112017002526A2 (pt) 2017-12-05
ECSP17014159A (es) 2017-05-31
EA201790332A1 (ru) 2017-06-30
KR20180066108A (ko) 2018-06-18
EP3193925A2 (en) 2017-07-26
MY203284A (en) 2024-06-21
JP2017523220A (ja) 2017-08-17
PE20170392A1 (es) 2017-04-07

Similar Documents

Publication Publication Date Title
AU2020267276B2 (en) Adjunctive therapy with 25-hydroxyvitamin d
US11738033B2 (en) Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
ES2496915T3 (es) Composiciones orales de liberación controlada que comprenden un compuesto de vitamina D y un soporte céreo
CA2882048C (en) Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
AU2017253821A1 (en) Methods of vitamin D treatment
CA2998426C (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
JP2022519789A (ja) カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物
EA045627B1 (ru) Фармацевтическая композиция и набор для лечения или предотвращения гипокальциемии
EA044066B1 (ru) Дополнительная терапия 25-гидроксивитамином d

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170307

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200805

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220907

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230614

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220907

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230614

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230307

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20231207

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20231113

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20230614

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230307

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20220907

X601 Decision of rejection after re-examination